Johnson & Johnson (JNJ) plans to inject a whopping $2 billion in order to enhance its manufacturing sector in the US, amidst looming drug tariffs. This expansion notably includes creation of new jobs and solidifies JNJ's commitment to domestic manufacturing. It's a worthy mention that the company's stock continues to do well despite the US tariffs, with the firm adding an additional $2 billion to its initial $55 billion US investment. In terms of growth, several notable partners increased their holdings, including Level Four Advisory Services LLC, Candriam S.C.A., Erste Asset Management GmbH, Allstate Corp, amongst others. This resulted in JNJ's shares reaching a new 52-week high. Conversely, some companies reduced their stake, like Bowen Hanes &Co. Inc., Van Lanschot Kempen Investment Management N.V., and RWA Wealth Partners LLC. Unfortunately, JNJ faces a $42M penalty after a jury ruled its talc caused a man's cancer. On brighter note, JNJ has been lauded for its approach to pricing and it has achieved FDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer. Lastly, J&J was named to Fortune’s 2025 America’s Most Innovative Companies list.
Johnson Johnson JNJ News Analytics from Thu, 26 Sep 2024 07:00:00 GMT to Sat, 23 Aug 2025 23:30:07 GMT -
Rating 8
- Innovation 7
- Information 7
- Rumor 2
